MORAb-004

DRUG3 trials

Sponsors

Morphotek, Eisai Co., Ltd.

Conditions

Colorectal CancerMetastatic Colorectal CancerMetastatic Soft Tissue SarcomaSolid Tumor

Phase 1

A Phase 1 Study of MORAb-004 in Patients With Solid Tumor (Study: MORAb-004-J081-103)

CompletedNCT01773434

Eisai Co., Ltd.Solid Tumor

Start: 2012-12-31End: 2016-10-31Updated: 2016-11-10

Phase 2

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

TerminatedNCT01507545

MorphotekColorectal Cancer, Metastatic Colorectal Cancer

Start: 2012-03-27End: 2013-10-20Updated: 2022-05-06

Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation

CompletedNCT01574716

MorphotekMetastatic Soft Tissue Sarcoma

Start: 2012-08-07End: 2016-08-02Updated: 2019-08-21

Related Papers

A phase I study of ontuxizumab, a humanized monoclonal antibody targeting endosialin, in Japanese patients with solid tumors.

2019-01-098 citations

Genomic amplification of CDK4 in dedifferentiated liposarcomas as a predictive biomarker for microtubule disrupting agents.

Journal of Clinical Oncology2018-05-20

A study of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft tissue sarcoma.

Journal of Clinical Oncology2015-05-201 citations

Phase I study of ontuxizumab, a humanized monoclonal antibody (mAb) recognizing endosialin in Japanese patients (pts) with hepatocellular carcinoma (HCC).

Journal of Clinical Oncology2015-05-201 citations